Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India

Indian Journal of Medical Research

Volumn 132, Issue 11, 2010, Pages 509-512

  Rajesh, Lakshmi ^a   Ramesh, K ^a   Hanna, Luke Elizabeth ^a   Narayanan, P R ^a   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Drug resistance; HIV; Nevirapine; Pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INDIA; NONHUMAN; PILOT STUDY; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PUERPERIUM; SINGLE DRUG DOSE; TREATMENT OUTCOME; VIRUS DETECTION; ANTIVIRAL RESISTANCE; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOLECULAR SEQUENCE DATA; MUTATION; NEVIRAPINE; POLYMERASE CHAIN REACTION; PREGNANCY; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 78649467544     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. UNAIDS WHO. HIV/AIDS Epidemic update. Epidemiological fact sheet on HIV/AIDS, India- WHO/UNAIDS. 2008 update131. 2007. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp, accessed on December 22, 2008.
2. NACO. Guidelines for HIV care and treatment in infants and children. 2006. Available at: http://www.nacoonline.org/Quick_Links/Publication/Treatment_Care__Support/Operational__Technical_guidelines_and_policies/Guidelines_for_HIV_Care_and_Treatment/, accessed o December 22, 2008.
3. Giaquinto C, Rampon O, de Rossi A. Antiretroviral therapy for prevention of mother to child transmission. Clin Drug Invest 2006; 26: 611-27.
4. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Rapid Advice, WHO guidelines. Geneva: WHO; 2009.
5. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351: 229-40.
6. ViroSeq HIV-1 Genotyping System v2. 0, User manual. USA: Celera Diagnostics; 2004.
7. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-45.
8. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 Update. PLoS One 2009; 4: e4724.
9. Lakshmi R, Ramesh K, Narayanan PR, Swaminathan S. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients. AIDS Res Hum Retroviruses 2009, 25: 1179-85.
10. Lall M, Gupta RM, Sen S, Kapila K, Tripathy SP, Paranjape RS. Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India. AIDS Res Hum Retroviruses 2008; 24: 987-90.
11. Balakrishnan P, Kumarasamy N, Kantor R, Solomon S, Vidya S, Mayer KH, et al. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses 2005; 21: 301-5.
12. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al. Nevirapine resistance in women with HIV-1 subtype C compared to subtype A and D after administration of single dose nevirapine. J Infect Dis 2005; 192: 30-6.
13. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36: 1009-2.
14. Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, Jariyasethpong T, et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: A multi-country, prospective cohort study. PLoS Med 2010; 7: e1000233.
15. Moorthy A, Gupta A, Bhosala R, Tripathy S, Sastry J, Kulkarni S, et al. Nevirapine resistance and breast - milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLos One 2009; 4: e4096.
16. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-7.
17. Lidstrom J, Hoover DR, Kumwenda N, Li Q, Mofenson LM, Fowler MG, et al, Comparison of nevirapine (NVP) resistance among HIV infected infants who received extended NVP plus zidovudine prophylaxis vs. extended NVP prophylaxis alone: the PEPI-Malwi study. Conference on Retrovirus and Opportunistic Infections 2010, abstract 918.
18. Chaix M. Addition of 3 days of ZDV+3TC postpartum to a short course of ZDV+3TC and single dose NVP provides low rate of NVP resistance mutations and high efficacy in preventing postpartum HIV-1 transmission. Conference on Retrovirus and Opportunistic Infections 2005; abstract 72 LB: Boston.